Takeda Signs Agreement With Galaxy Biotech for HuL2G7

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

TOKYO, Japan—Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

Articles in this issue
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemo
Triple Targeted Therapy Is Tested in Pts With Solid Tumors
FDA Approves Three-Drug Combination Tablet for HIV-1
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
No Significant QOL Differences for Raloxifene and Tamoxifen
Amrubicin Appears Promising in Small-Cell Lung Cancer
R-MP Active in Older Pts With Newly Diagnosed Myeloma
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trials
Takeda Signs Agreement With Galaxy Biotech for HuL2G7
Experimental Regimens Fail to Boost Pancreatic Survival
Adding Bortezomib Ups Dual Transplant Results in Myeloma
Demand Spurs Efforts to Improve Recruitment, Retention
Why Has Mortality Related to Pancreatectomy Declined?
Phase III Trial Finds XP as Efficacious as EP as First-Line Therapy for Metastatic Breast Cancer
Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

TTFields Plus Temozolomide/Pembrolizumab Controls Tumors in Glioblastoma

Ariana Pelosci
November 11th 2024
Article

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

PET Imaging Agent Earns FDA Priority Review in Recurrent Glioma

Russ Conroy
October 25th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

177Lu-Dotatate Improves PFS in Recurrent Meningioma

Ariana Pelosci
October 1st 2024
Article

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma | Image Credit: © Dr_Microbe - stock.adobe.com.

Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma

Russ Conroy
October 1st 2024
Article

UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.